Your session is about to expire
← Back to Search
Intensive Antiretroviral Therapy for HIV/AIDS in Infants
Study Summary
This trial will study whether earlier ART treatment can help HIV-infected infants achieve remission.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a condition where my lymphocytes grow abnormally.I haven't had cancer in the last 5 years, except for skin cancer.I am a mother with confirmed or presumed HIV, willing to consent for me and my infant.I have a history of cancer.
- Group 1: Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/r
- Group 2: Cohort 1, Regimen 2R: 2 NRTIs + NVP + RAL
- Group 3: Cohort 2, Regimen 2R: 2 NRTIs + NVP + RAL
- Group 4: Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/r
- Group 5: Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the recruitment stage of this experiment ongoing?
"Affirmative. Clinicaltrials.gov indicates that this trial, which was initially published on January 23rd 2015, is still recruiting participants. Approximately 905 people are required to be recruited from 15 separate sites."
What pathologies are Nucleoside Reverse Transcriptase Inhibitors (NRTIs) typically employed to address?
"NRTIs, or Nucleoside Reverse Transcriptase Inhibitors, is typically used to prevent occupational exposure to HIV. It also has applications in treating sars-cov-2 positive patients and mild to moderate cases of COVID-19 as well as chronic hepatitis c genotype 1a."
What additional research has been conducted on Nucleoside Reverse Transcriptase Inhibitors (NRTIs)?
"The first studies on nucleoside reverse transcriptase inhibitors (NRTIs) were conducted at University of Zurich in 2002. Subsequently, there have been 731 completed trials and currently 17 active experiments are running; many taking place within Los Angeles County."
How many participants is the research team recruiting for this investigation?
"For this clinical trial to reach its desired result, 905 participants who meet the given criteria need to enroll. Those interested in participating can find locations at David Geffen School of Medicine at UCLA NICHD CRS (Los Angeles) and University of California UC San Diego CRS- Mother-Child-Adolescent HIV Program (La Jolla)."
What is the geographic scope of this clinical investigation?
"To enroll in this medical trial, patients may visit one of 15 different enrolment sites such as David Geffen School of Medicine at UCLA NICHD CRS in Los Angeles or the University of California's UC San Diego CRS- Mother-Child-Adolescent HIV Program. Additionally, Emory University School of Medicine NICHD CRS is another location for recruitment along with 12 other centres."
Share this study with friends
Copy Link
Messenger